多基因基因组分类器与临床参数预测东南亚细胞学不确定甲状腺结节恶性风险的表现
该前瞻性多中心盲法研究纳入132例患者共134个细胞学不确定甲状腺结节,评估ThyroSeq v3多基因检测及临床参数预测恶性的效能。结果显示ThyroSeq阴性率37.3%,Bethesda III-IV结节中42%可避免诊断性手术;检测敏感度89.6%、特异度73.7%、阴性预测值84.0%、阳性预测值82.1%。多基因检测阳性是比临床参数更强的恶性预测因子。
要点
- Bethesda III-IV结节中42%可因多基因检测阴性避免诊断性手术。
- ThyroSeq v3敏感度89.6%、特异度73.7%、阴性预测值84.0%、阳性预测值82.1%。
- 多基因检测阳性比临床参数更强预测恶性,高危超声特征亦相关。
核心结论
- 在东南亚细胞学不确定甲状腺结节队列中,多基因检测可使42%的Bethesda III-IV结节患者避免诊断性手术。
- 多基因检测阳性是比临床参数更强的恶性预测因子。
研究设计与样本
- 前瞻性、多中心、盲法研究,纳入132例患者共134个结节。
- 对临床或离体细针穿刺样本行ThyroSeq v3多基因检测,并进行集中病理 review。
主要发现
- 134个结节中Bethesda III类占61%、IV类占20%、V类占19%,组织学恶性占56%。
- ThyroSeq在所有FNA样本中阴性率为37.3%,在Bethesda III-IV类结节中阴性率为42%。
- 阳性样本中RAS样改变占41.7%、BRAF样占22.6%、高风险改变占17.9%。
- 与北美患者相比,Bethesda III和IV类中RAS样突变(尤其NRAS)比例更高,Bethesda III类中BRAF样突变更多。
- 检测敏感度89.6%、特异度73.7%、阴性预测值84.0%、阳性预测值82.1%。
临床怎么用
- 对Bethesda III-IV类细胞学不确定甲状腺结节,可借助ThyroSeq v3阴性结果减少诊断性手术。
- 多基因检测阳性应视为比临床参数更强的恶性预测信号,需结合ATA超声高危特征综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most thyroid nodules are benign. It is important to determine the likelihood of malignancy in such nodules to avoid unnecessary surgery. The primary objective of this study was to characterize the genetic landscape and the performance of a multigene genomic classifier in fine-needle aspiration (FNA) biopsies of cytologically indeterminate thyroid nodules in a Southeast Asian cohort. The secondary objective was to assess the predictive contribution of clinical characteristics to thyroid malignancy. METHODS: This prospective, multicenter, blinded study included 132 patients with 134 nodules. Molecular testing (MT) with ThyroSeq v3 was performed on clinical or ex-vivo FNA samples. Centralized pathology review also was performed. RESULTS: Of 134 nodules, consisting of 61% Bethesda category III, 20% category IV, and 19% category V cytology, and 56% were histologically malignant. ThyroSeq yielded negative results in 37.3% of all FNA samples and in 42% of Bethesda category III-IV cytology nodules. Most positive samples had RAS-like (41.7%), followed by BRAF-like (22.6%), and high-risk (17.9%) alterations. Compared with North American patients, the authors observed a higher proportion of RAS-like mutations, specifically NRAS, in Bethesda categories III and IV and more BRAF-like mutations in Bethesda category III. The test had sensitivity, specificity, negative predictive value, and positive predictive value of 89.6%, 73.7%, 84.0%, and 82.1%, respectively. The risk of malignancy was predicted by positive MT and high-suspicion ultrasound characteristics according to American Thyroid Association criteria. CONCLUSIONS: Even in the current Southeast Asian cohort with nodules that had a high pretest cancer probability, MT could lead to potential avoidance of diagnostic surgery in 42% of patients with Bethesda category III-IV nodules. MT positivity was a stronger predictor of malignancy than clinical parameters.
引用
- Yang SP, Nga ME, Bundele MM, et al. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules. Cancer Cytopathol. 2024. PMID: 38319805. doi:10.1002/cncy.22796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。